Knight Therapeutics Inc. announces voting results from the Annual General Meeting

About this update from Knight Therapeutics, Inc.

[{"type":"text","content":"Knight Therapeutics Inc. announces voting results from the Annual General Meeting\n\n\n\n MONTREAL, May 07, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX:GUD) (\"Knight\" or the \"Corporation\") a pan-American (ex-US) specialty pharmaceutical company, announced today the voting results from the Annual General Meeting of the Shareholders held virtually in Montreal, Quebec (\"Meeting\").\n \n\n\n Election of Directors\n \n\n\n Each director nominee listed in the Management Information Circular dated April 4, 2025 (\"Circular\") was elected as Director of the Corporation at the Meeting. Shareholders present in person or represented by proxy at the Meeting voted as follows:\n \n\n\n\n\n DIRECTOR NOMINEE\n \n\n\n\n OUTCOME\n \n\n\n\n VOTES\n \n FOR\n \n\n\n\n % FOR\n \n\n\n\n VOTES\n \n AGAINST\n \n\n\n\n %\n \n\n\n AGAINST\n \n\n\n\n\n Jonathan Ross Goodman\n \n\n Elected\n \n\n 59,911,976\n \n\n 96.70%\n \n\n 2,041,772\n \n\n 3.30%\n \n\n\n\n James C. Gale\n \n\n Elected\n \n\n 61,421,942\n \n\n 99.14%\n \n\n 531,806\n \n\n 0.86%\n \n\n\n\n Samira Sakhia\n \n\n Elected\n \n\n 61,868,351\n \n\n 99.86%\n \n\n 85,397\n \n\n 0.14%\n \n\n\n\n Robert N. Lande\n \n\n Elected\n \n\n 61,742,628\n \n\n 99.66%\n \n\n 211,120\n \n\n 0.34%\n \n\n\n\n Michael J. Tremblay\n \n\n Elected\n \n\n 59,558,152\n \n\n 96.13%\n \n\n 2,395,596\n \n\n 3.87%\n \n\n\n\n Nicolás Sujoy\n \n\n Elected\n \n\n 61,749,390\n \n\n 99.67%\n \n\n 204,358\n \n\n 0.33%\n \n\n\n\n Janice Murray\n \n\n Elected\n \n\n 61,750,229\n \n\n 99.67%\n \n\n 203,519\n \n\n 0.33%\n \n\n\n\n\n\n Appointment of external Auditors\n \n\n\n Ernst & Young LLP were appointed as external auditors of the Corporation for the next year by a majority of the votes cast by the shareholders present or represented by proxy, and the directors were authorized to determine their remuneration. Shareholders present in person or represented by proxy at the Meeting voted as follows:\n \n\n\n\n\n OUTCOME\n \n\n\n\n VOTES FOR\n \n\n\n\n % FOR\n \n\n\n\n VOTES WITHHELD\n \n\n\n\n % WITHHELD\n \n\n\n\n\n Appointed\n \n\n 62,087,609\n \n\n 99.60%\n \n\n 248,512\n \n\n 0.40%\n \n\n\n\n\n\n Renewal of unallocated rights under the Corporation’s employee and director share purchase plan\n \n\n\n The resolution to approve the renewal of unallocated rights under the Corporation’s empl...

More updates from Knight Therapeutics, Inc.